Xenon Pharmaceuticals Inc (NAS:XENE)
$ 43.33 1.62 (3.88%) Market Cap: 3.28 Bil Enterprise Value: 2.45 Bil PE Ratio: 0 PB Ratio: 3.88 GF Score: 41/100

Xenon Pharmaceuticals Inc. - Special Call Transcript

Dec 02, 2019 / 01:30PM GMT
Release Date Price: $12.31 (+4.06%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Xenon Pharmaceuticals Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Jodi Regts. Thank you. Please go ahead.

Jodi Regts
Xenon Pharmaceuticals Inc. - VP of Corporate Affairs & IR

Thanks, Jimmy. Good morning. Thank you for joining us on the call and webcast to provide a corporate update and discuss this morning's announcement regarding a license and collaboration agreement with Neurocrine Biosciences. Joining me are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following their comments today, we will open up the call to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and results from clinical trials and other development activities,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot